Influenza A (H1N1) vaccination in Systemic Lupus Erythematosus patients

Authors

  • Fernando Salvador Unidade de Imunologia Clínica, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal
  • Sofia Ribeiro Unidade de Imunologia Clínica, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal
  • Cátia Macedo Unidade de Imunologia Clínica, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal
  • João Neves Unidade de Imunologia Clínica, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal
  • Sofia Teixeira Unidade de Imunologia Clínica, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal
  • Fátima Farinha Unidade de Imunologia Clínica, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal
  • Isabel Almeida Unidade de Imunologia Clínica, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal
  • Carlos Vasconcelos Unidade de Imunologia Clínica, Hospital Santo António, Centro Hospitalar do Porto, Porto, Portugal

Keywords:

Systemic Lupus Erythematosus, H1N1 virus, vaccination, safety

Abstract

Objective: To evaluate retrospectively the use of Influenza A (H1N1)
vaccine and its effects on the Systemic Lupus Erythematosus
(SLE) adult patients followed in the Clinical Immunology Unit of
Hospital Santo Antonio – Porto, Portugal.
Material and Methods: A telephone survey was carried out,
asking patients whether they had influenza A medical diagnosis.
They were also asked whether the vaccine had been proposed
and administered and if any local and/or systemic side effects
had emerged. Patients who took the vaccine, were assessed
regarding the effect of the disease activity on a numerical scale
from 0 (no active disease) to 10 (very active) the month before
and after vaccination.
Results: Of 318 SLE patients followed in the Unit, 186 (mean
age 43 ± 13; 91% female) were contacted. Vaccination was
offered to 37% of them (68) and was administered to 28 patients
(41%). 72% of vaccinated patients had local adverse reactions and
31% systemic. No influenza infection was diagnosed in vaccinated
patients. The mean global assessment of disease activity in the
month preceding and following the administration of the vaccine
was 3. The mean scale variation was 0.
Conclusion: Despite the Health Portuguese Department recommendations for H1N1 vaccine, a significant number of SLE
patients were not vaccinated either because they had not been
proposed to, either by their poor compliance. Although a significant incidence of local and systemic side effects there was no
change in SLE activity.

Downloads

Download data is not yet available.

References

Glück T, Muller-Ladner U. Vaccination in Patients with Chronic Rheumatic or Autoimmune Diseases. Clinical Infectious Diseases 2008;46:1459-1465.

Alarcon GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin North Am 2006;20:849-875.

Bouza E, Moya JG, Muñoz P. Infections in systemic lupus eythematosus and rheumatoid arthritis. Infec Dis Clin North Am 2001;15:335-361.

Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1157-1160.

Glück T, Kiefmann B, Grohmann M, Falk W, Straub RH, Scölmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 2005;32:1473-1480.

Ristow SC, Douglas RG Jr., Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978;88:786-789.

Louie JS, Nies KM, Shoji KT, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978;88:790-792.

Brodman R, Gilfillan R, Glass D, Shur PH. Influenza vaccine response in systemic lupus erythematosus. Ann Intern Med 1978;88:735-740.

Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R. Influenza immunization in systemic lupus erythematosus. A double-blind trial. Ann Intern Med 1978;88:729-734.

Herron A, Dettleff G, Hixon B et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA 1979;242:53-56.

Holvast A, Huckriede A, Wilschut J et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rhem Dis 2006;65:913-918.

Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2003;30:2295-2296.

Wallin L, Quntilio W, Locatelli F, Cassel A, Silva MB, Skare TL. Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol Port 2009;34:498-502.

Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clinical and Developmental Immunology 2006;13:373-375.

Mercado U, Acosta H, Avendaño L. Influenza vaccination of patients with systemic lupus erythematosus. Rev Invest Clin 2004;56:16-20.

Van Assen S, Agmone-Levin N, Elkayam O et al. EULAR recommendations for vaccination in adult patients with autoimmune inflmmatory rheumatic diseases. Ann Rheum Dis 2011; 70(3):414-422.

Van Assen S, Elkayam O, Agmon-Levin N et al. Vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systemic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Autoimmun Rev 2011 2011; 10(6):341-352.

Gripe – Informação estatística. Direcção-Geral da Saúde 2010 http://www.portaldasaude.pt/NR/rdonlyres/E1F27E5D-3A2D-43DE-950A-26FEC84F6816/0/dadosestat%C3%ADsticosGripeA.pdf. Acedido em 29 Outubro de 2011.

Campanha de vacinação contra o vírus da gripe pandémica H1N1 (2009). Circular Normativa n.º17. Direcção-Geral da Saúde. 14 de Outubro de 2009 http://www.dgs.pt. Acedido em 29 de Outubro de 2011.

Classification and Response Criteria for Rheumatic Diseases. American College of Rheumatology. 1997 http://www.rheumatology.org/practice/clinical/classification/index.asp. Acedido em 23 de Outubro de 2010.

Wallace JD. Dubois’ Lupus Erythematosus.Philadelphia: Lippincott Williams & Wilkins, 2007:34-44

Vasconcelos C. Epidemiologia Clínica do Lúpus Eritematoso Sistémico no Norte de Portugal:2007:71-73.

Greenber ME, Lai HM, Hartel GF et al. Response to a Monovalent 2009 Influenza A (H1N1) Vaccine. N Eng J Med 2009; 361:2405-2413.

Saad CG, Borba EF, Aikawa NE et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011; 70(6):1068-1073.

Gabay C, Bel M, Combescure C et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011; 63(6):1486-1496.

Elkayam O, Amir S, Mendelson E et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) vírus among patients with rheumatic diseases. Arthritis Care Res (Hoboken) 2011; 63(7):1062-1067

Additional Files

Published

2012-09-28

How to Cite

1.
Salvador F, Ribeiro S, Macedo C, Neves J, Teixeira S, Farinha F, Almeida I, Vasconcelos C. Influenza A (H1N1) vaccination in Systemic Lupus Erythematosus patients. RPMI [Internet]. 2012 Sep. 28 [cited 2024 May 19];19(3):140-4. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/1159

Issue

Section

Original Articles

Most read articles by the same author(s)

1 2 > >>